论文部分内容阅读
目的探讨运用阿奇霉素和红霉素治疗支原体肺炎的临床有效率、临床症状恢复时间及不良反应对比分析。方法收集郑州大学第一附属医院2011年1月至2012年12月收治的支原体肺炎126例,将其随机分成两组,观察其分别运用阿奇霉素和红霉素的临床有效率、临床症状恢复时间及不良反应。结果阿奇霉素组总有效率为93.85%,红霉素组总有效率为77.05%,二者相比差异有统计学意义;阿奇霉素组临床症状恢复时间明显优于红霉素组,二者比较差异有统计学意义;阿奇霉素组不良反应发生率(10.77%)明显低于红霉素组(44.26%),二者比较差异有统计学意义(P<0.05)。结论阿奇霉素治疗支原体肺炎具有较高的安全性。可作为治疗支原体肺炎的首选抗生素,值得临床广泛推广。
Objective To investigate the use of azithromycin and erythromycin in the treatment of mycoplasma pneumonia clinical efficacy, clinical symptoms recovery time and adverse reactions comparative analysis. Methods 126 cases of mycoplasma pneumonia admitted from January 2011 to December 2012 in the First Affiliated Hospital of Zhengzhou University were collected and randomly divided into two groups. The clinical efficacy, the recovery time of clinical symptoms and the clinical efficacy of azithromycin and erythromycin Adverse reactions. Results The total effective rate of azithromycin group was 93.85%, the total effective rate of erythromycin group was 77.05%, the difference was statistically significant; the recovery time of clinical symptoms in azithromycin group was significantly better than that of erythromycin group, the difference was The incidence of adverse reactions in azithromycin group was significantly lower than that in erythromycin group (10.77% vs 44.26%, P <0.05). Conclusion Azithromycin treatment of mycoplasma pneumonia has higher safety. Can be used as the treatment of mycoplasma pneumoniae preferred antibiotics, it is widely recommended in clinical.